var data={"title":"Atovaquone and proguanil: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Atovaquone and proguanil: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5680?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=atovaquone-and-proguanil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Atovaquone and proguanil: Patient drug information&quot;</a> and <a href=\"topic.htm?path=atovaquone-and-proguanil-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Atovaquone and proguanil: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137595\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Malarone&reg;</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137596\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Malarone&reg;;</li>\n      <li>Malarone&reg; Pediatric</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137614\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antimalarial Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137598\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prevention of malaria:</b> Oral: Atovaquone/proguanil 250 mg/100 mg once daily; start 1-2 days prior to entering a malaria-endemic area, continue throughout the stay and for 7 days after returning. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Treatment of acute malaria:</b> Oral: Atovaquone/proguanil 1000 mg/400 mg as a single dose, once daily for 3 consecutive days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137608\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=atovaquone-and-proguanil-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Atovaquone and proguanil: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Prevention of malaria:</b> Oral: Start 1-2 days prior to entering a malaria-endemic area, continue throughout the stay and for 7 days after returning. Take as a single dose, once daily. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-8 kg (off-label dosing): Atovaquone/proguanil 31.25 mg/12.5 mg (Boggild, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9-10 kg (off-label dosing): Atovaquone/proguanil 46.8 mg/18.75 mg (Boggild, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">11-20 kg: Atovaquone/proguanil 62.5 mg/25 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">21-30 kg: Atovaquone/proguanil 125 mg/50 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">31-40 kg: Atovaquone/proguanil 187.5 mg/75 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&gt;40 kg: Atovaquone/proguanil 250 mg/100 mg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Treatment of acute malaria:</b> Oral: Take as a single dose, once daily for 3 consecutive days. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5-8 kg: Atovaquone/proguanil 125 mg/50 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">9-10 kg: Atovaquone/proguanil 187.5 mg/75 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">11-20 kg: Atovaquone/proguanil 250 mg/100 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">21-30 kg: Atovaquone/proguanil 500 mg/200 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">31-40 kg: Atovaquone/proguanil 750 mg/300 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&gt;40 kg: Atovaquone/proguanil 1000 mg/400 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137599\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137600\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &lt;30 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prophylaxis: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Treatment: No dosage adjustment necessary; however, use with extreme caution and only if the benefits outweigh the risks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137601\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild-to-moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe impairment; No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137574\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Malarone: Atovaquone 250 mg and proguanil hydrochloride 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: Atovaquone 250 mg and proguanil hydrochloride 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral [pediatric]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Malarone: Atovaquone 62.5 mg and proguanil hydrochloride 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: Atovaquone 62.5 mg and proguanil hydrochloride 25 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137560\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137577\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with food or milk-based drink at the same time each day. If vomiting occurs within 1 hour of administration, repeat the dose. For patients who have difficulty swallowing tablets, tablets may be crushed and mixed with condensed milk just prior to administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137575\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malaria prevention:</b> Prophylaxis of <i>Plasmodium falciparum</i> malaria, including areas where chloroquine resistance has been reported</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malaria treatment:</b> Treatment of acute, uncomplicated <i>P. falciparum</i> malaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28800043\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Malarone may be confused with mefloquine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137567\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">The following adverse reactions were reported in patients being treated for malaria. When used for prophylaxis, reactions are similar to those seen with placebo.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (17%), nausea (12%), vomiting (children: 10% to 13%; adults: 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (27%; increased liver function test values typically normalized after ~ 4 weeks), increased serum AST (17%; increased liver function test values typically normalized after ~4 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (10%), dizziness (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (children: 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (children: 6%; adults: 8%), anorexia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis (rare), anemia (rare), angioedema, cholestasis, erythema multiforme (rare), hallucination, hepatic failure (case report), hepatitis (rare), neutropenia, pancytopenia (with severe renal impairment), psychotic reaction (rare), seizure (rare), skin photosensitivity, skin rash, Stevens-Johnson syndrome (rare), stomatitis, urticaria, vasculitis (rare)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137580\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to atovaquone, proguanil, or any component of the formulation; prophylactic use in severe renal impairment (CrCl &lt;30 mL/minute)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137564\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse events:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Increased transaminase levels and hepatitis have been reported with prophylactic use; single case report of hepatic failure requiring transplantation documented. Monitor closely and use caution in patients with existing hepatic impairment. Elevations in AST/ALT may persist for up to 4 weeks following treatment (Looareesuwan, 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diarrhea/vomiting: Absorption of atovaquone may be decreased in patients who have diarrhea or vomiting; monitor closely and consider use of an antiemetic. If severe, consider use of an alternative antimalarial.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Malaria: Appropriate use: Not indicated for cerebral malaria or other severe manifestations of complicated malaria. Delayed cases of <i>P. falciparum</i> malaria may occur after stopping prophylaxis; travelers returning from endemic areas who develop febrile illnesses should be evaluated for malaria. Recrudescent infections or infections following prophylaxis with this agent should be treated with alternative agent(s). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with preexisting renal disease. May use with caution for treatment of malaria in patients with severe renal impairment (CrCl &lt;30 mL/minute) if benefit outweighs risk. Contraindicated for prophylactic use in severe renal impairment due to the risk of pancytopenia in patients with severe renal impairment treated with proguanil.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Obesity: Treatment failures have been reported in patients &gt;100 kg (case reports); follow-up monitoring is recommended (Durand, 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137609\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137569\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8704&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May decrease the serum concentration of Proguanil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of Atovaquone. Management: Consider alternatives to the use of atovaquone with efavirenz when possible.  If this combination must be used, monitor for evidence of reduced atovaquone clinical effectiveness.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide: Atovaquone may increase the serum concentration of Etoposide.  Management: Consider separating the administration of atovaquone and etoposide by at least 1 to 2 days.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide Phosphate: Atovaquone may increase the serum concentration of Etoposide Phosphate.  Management: Consider separating the administration of atovaquone and etoposide by at least 1 to 2 days.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Atovaquone may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May decrease the serum concentration of Atovaquone. Management: Consider alternatives to metoclopramide when possible; atovaquone should only be used with metoclopramide if no other antiemetics are available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyrimethamine: May enhance the adverse/toxic effect of Proguanil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Atovaquone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May decrease the serum concentration of Atovaquone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracycline: May decrease the serum concentration of Atovaquone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Proguanil may diminish the therapeutic effect of Typhoid Vaccine. This applies only to the oral (live) typhoid vaccine.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with proguanil. When possible, proguanil should not be started within 10 days of the last vaccine dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Proguanil may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137591\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Atovaquone taken with dietary fat significantly increases the rate and extent of absorption; AUC is increased 2-3 times and C<sub>max</sub> is increased 5 times as compared to administration during a fasted state. Management: Administer with food or milk-based drink at the same time each day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137571\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137582\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed with the combination of atovaquone/proguanil in animal reproduction studies. The pharmacokinetics of atovaquone and proguanil may be altered during pregnancy (Wilby 2011). Malaria infection in pregnant women may be more severe than in nonpregnant women. Because <i>P. falciparum</i> malaria can cause maternal death and fetal loss, pregnant women traveling to malaria-endemic areas must use personal protection against mosquito bites. Atovaquone/proguanil may be used as an alternative treatment of malaria in pregnant women; consult current CDC guidelines (CDC 2013). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9760124\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Small quantities of proguanil are found in breast milk. This combination is not recommended if nursing infants &lt;5 kg (safety data is limited concerning therapeutic use in infants &lt;5 kg) (Boggild 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137583\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Must be taken with food or milk-based drink.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9760127\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver and renal function; closely monitor response to treatment in patients with vomiting or diarrhea and in patients &gt;100 kg (Durand, 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137563\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Atovaquone: Selectively inhibits parasite mitochondrial electron transport. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Proguanil: The metabolite cycloguanil inhibits dihydrofolate reductase, disrupting deoxythymidylate synthesis. Together, atovaquone/cycloguanil affect the erythrocytic and exoerythrocytic stages of development.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137579\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atovaquone: The rate and extent of absorption is increased when administered with dietary fat. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proguanil: Extensive </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atovaquone: Children and Adults: ~8.8 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proguanil: Children &gt;15 years and Adults and 31-110 kg: 1617-2502 L; Pediatric patients &le;15 years and 11-56 kg: 462-966 L; concentrated in erythrocytes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atovaquone: &gt;99%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proguanil: 75%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Proguanil: Hepatic to active metabolites, cycloguanil (via CYP2C19) and 4-chlorophenylbiguanide</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Atovaquone/proguanil: 23% when administered with food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atovaquone: 2-3 days (adults), 1-2 days (children)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proguanil: 12-21 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Atovaquone: Feces (&gt;94% as unchanged drug); urine (&lt;0.6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Proguanil: Urine (40% to 60%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137581\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Atovaquone-Proguanil HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">62.5-25 mg (100): $253.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-100 mg (100): $714.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Malarone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">62.5-25 mg (100): $298.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-100 mg (24): $197.76</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137584\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Malanil (TH, ZW);</li>\n      <li>Malarone (AT, AU, BB, BE, BH, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, IE, IL, IS, IT, JO, JP, KR, KW, LT, LU, MT, MY, NL, NO, NZ, PE, PL, PT, QA, SA, SE, SG, SI, SK);</li>\n      <li>Reprapog (MT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Boggild AK, Parise ME, Lewis LS, et al, &ldquo;Atovaquone-Proguanil: Report From The CDC Expert Meeting On Malaria Chemoprophylaxis (II),&rdquo; <i>Am J Trop Med Hyg</i>, 2007, 76(2):208-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-and-proguanil-drug-information/abstract-text/17297027/pubmed\" target=\"_blank\" id=\"17297027\">17297027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States.&rdquo; Available at <a href=\"http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf\" target=\"_blank\">http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Treatment of Malaria (Guidelines for Clinicians).&rdquo; Available at <a href=\"http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf\" target=\"_blank\">http://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durand R, Prendki V, Cailhol J, et al, &ldquo;<i>Plasmodium falciparum</i> Malaria and Atovaquone-Proguanil Treatment Failure,&rdquo; <i>Emerg Infect Dis</i>, 2008, 14(2):320-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-and-proguanil-drug-information/abstract-text/18258131/pubmed\" target=\"_blank\" id=\"18258131\">18258131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Looareesuwan S, Wilairatana P, Chalermarut K, et al. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute <i>Plasmodium falciparum</i> malaria in Thailand. <i>Am J Trop Med Hyg</i>. 1999;60(4):526-532.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-and-proguanil-drug-information/abstract-text/10348224/pubmed\" target=\"_blank\" id=\"10348224\">10348224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malarone (atovaquone and proguanil hydrochloride) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilby KJ, Ensom MH. Pharmacokinetics of antimalarials in pregnancy: a systematic review. <i>Clin Pharmacokinet</i>. 2011;50(11):705-723.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atovaquone-and-proguanil-drug-information/abstract-text/21973268 /pubmed\" target=\"_blank\" id=\"21973268 \">21973268 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8704 Version 121.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F137595\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F137596\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F137614\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F137598\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F137608\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F137599\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F137600\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F137601\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F137574\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F137560\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F137577\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F137575\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F28800043\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F137567\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F137580\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F137564\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F137609\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F137569\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F137591\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F137571\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F137582\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9760124\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F137583\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9760127\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F137563\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F137579\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F137581\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F137584\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8704|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=atovaquone-and-proguanil-patient-drug-information\" class=\"drug drug_patient\">Atovaquone and proguanil: Patient drug information</a></li><li><a href=\"topic.htm?path=atovaquone-and-proguanil-pediatric-drug-information\" class=\"drug drug_pediatric\">Atovaquone and proguanil: Pediatric drug information</a></li></ul></div></div>","javascript":null}